- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Potentially Undervalued Companies
U.S. Pharmaceuticals & Biotech Potentially Undervalued Companies
Results
403
Companies with a Value score of at least 3, ordered by Value score
403 companies
Aurinia Pharmaceuticals
Market Cap: US$1.6b
A biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs.
AUPH
US$12.27
7D
0.4%
1Y
82.9%
Actinium Pharmaceuticals
Market Cap: US$54.3m
Develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies.
ATNM
US$1.74
7D
1.8%
1Y
-17.5%
Protagonist Therapeutics
Market Cap: US$3.6b
A biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases.
PTGX
US$57.48
7D
2.3%
1Y
38.2%
CRISPR Therapeutics
Market Cap: US$4.9b
A gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform.
CRSP
US$54.32
7D
-5.7%
1Y
10.5%
Clinuvel Pharmaceuticals
Market Cap: US$646.6m
A biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally.
CLVL.F
US$7.96
7D
0%
1Y
n/a
Ipsen
Market Cap: US$9.6b
Operates as a biopharmaceutical company worldwide.
IPSE.F
US$113.13
7D
0%
1Y
n/a
Tyra Biosciences
Market Cap: US$624.1m
A clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States.
TYRA
US$11.71
7D
8.3%
1Y
-47.5%